A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

This study has been terminated.
(Sponsor decision not to enroll cohorts of combined SGN-35 and gemcitabine therapy.)
Information provided by (Responsible Party):
Seattle Genetics, Inc.
ClinicalTrials.gov Identifier:
First received: March 27, 2008
Last updated: December 17, 2014
Last verified: December 2014
This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.

Condition Intervention Phase
Disease, Hodgkin
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Drug: SGN-35
Drug: gemcitabine
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study of Weekly SGN-35 Monotherapy and in Combination With Gemcitabine in Patients With Relapsed/Refractory CD30-positive Hematologic Malignancies

Resource links provided by NLM:

Further study details as provided by Seattle Genetics, Inc.:

Primary Outcome Measures:
  • Incidence of adverse events and laboratory abnormalities [ Time Frame: 1 month after last dose ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • PK profile [ Time Frame: 2 months after last dose ] [ Designated as safety issue: No ]
  • Immunogenicity (anti-SGN-35 antibodies) [ Time Frame: 1 month after last dose ] [ Designated as safety issue: Yes ]
  • Anti-tumor activity [ Time Frame: 1 month after last dose ] [ Designated as safety issue: No ]

Enrollment: 44
Study Start Date: March 2008
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
SGN-35 alone or in combination with gemcitabine
Drug: SGN-35
IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
Other Name: brentuximab vedotin
Drug: gemcitabine
IV; 1000 mg/m2 weekly 3 out of 4 weeks
Other Name: Gemzar


Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed CD30-positive hematologic malignancy.
  • Patients with HL must have failed systemic chemotherapy.
  • Patients with other CD30-positive malignancies (including ALCL) must be beyond first remission or refractory to front line chemotherapy.
  • Patients must have measurable disease of at least 1.5 cm as documented by radiographic technique.

Exclusion Criteria:

  • Current diagnosis of primary cutaneous ALCL (systemic ALCL eligible).
  • History of allogeneic stem cell transplant.
  • Patients who have had previous treatment with any anti-CD30 antibody.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00649584

United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3300
United States, California
Stanford University Medical Center
Palo Alto, California, United States, 94305
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030-4003
Sponsors and Collaborators
Seattle Genetics, Inc.
Study Director: Dana Kennedy, PharmD Seattle Genetics, Inc.
  More Information

Responsible Party: Seattle Genetics, Inc.
ClinicalTrials.gov Identifier: NCT00649584     History of Changes
Other Study ID Numbers: SG035-0002
Study First Received: March 27, 2008
Last Updated: December 17, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Seattle Genetics, Inc.:
Antigens, CD30
Antibody-Drug Conjugate
Antibodies, Monoclonal
monomethyl auristatin E
Combined Modality Therapy
Drug Therapy
Lymphoma, Non-Hodgkin
Disease, Hodgkin
Lymphoma, Large-Cell, Anaplastic
Hematologic Diseases

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, T-Cell
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2015